Geneoscopy announced that the US Centers for Medicare and Medicaid Services revised its National Coverage Determination for colorectal cancer screening tests, adding coverage for ColoSense, the company’s stool-based RNA screening test. The decision updates the framework for colorectal screening assays and supports future RNA-based technologies if they meet FDA approval requirements. ColoSense was previously FDA-approved. Geneoscopy said the updated evidence supports high sensitivity for colorectal cancer and includes a sensitivity profile for advanced adenomas. The test detects colorectal neoplasia-associated RNA markers and occult hemoglobin in stool. Geneoscopy also noted a strategic collaboration with Labcorp to expand distribution of ColoSense through its network. The coverage aligns with clinical guideline recommendations for average-risk screening at a three-year interval.